A VLP-based vaccine against interleukin-1α protects mice from atherosclerosis

European Journal of Immunology

Volumn 43, Issue 3, 2013, Pages 716-722

  Tissot, Alain C ^a,g   Spohn, Gunther ^a   Jennings, Gary T ^a   Shamshiev, Abdijapar ^a,h   Kurrer, Michael O ^b   Windak, Renata ^c   Meier, Marco ^a   Viesti, Miriam ^a   Hersberger, Martin ^d   Kündig, Thomas M ^e   Ricci, Romeo ^f   Bachmann, Martin F ^a,e  

^a CYTOS BIOTECHNOLOGY AG   (Switzerland)

^b Pathologie Institut Enge   (Switzerland)

^c Selvita SA Park Life Science ul   (Poland)

^d UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^g ROCHE DIAGNOSTICS GMBH   (Germany)

^h Delenex Therapeutics AG   (Switzerland)

Author keywords

Antibodies; Atherosclerosis; Macrophages; Vaccination

Indexed keywords

APOLIPOPROTEIN E; CHLORDANE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; VASCULAR CELL ADHESION MOLECULE 1; VIRUS LIKE PARTICLE VACCINE;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; AORTA ROOT; ARTICLE; BACTERIOPHAGE; BLOOD VESSEL WALL; CELL INFILTRATION; CONTROLLED STUDY; DESCENDING AORTA; DIET; DISEASE COURSE; DISEASE MODEL; DRUG CONJUGATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS LIKE AGENT;

ANIMALS; ANTIBODIES; ANTIBODIES, NEUTRALIZING; APOLIPOPROTEINS E; ATHEROSCLEROSIS; INFLAMMATION; INTERLEUKIN-1ALPHA; MALE; MICE; MICE, KNOCKOUT; PLAQUE, ATHEROSCLEROTIC; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84874972949     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201242687     Document Type: Article

References (35)

1. Lusis, A. J., Atherosclerosis. Nature 2000. 407: 233-241.
2. Libby, P., Inflammation in atherosclerosis. Nature 2002. 420: 868-874.
3. Ross, R., Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 1999. 340: 115-126.
4. Dinarello, C. A., Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 2009. 27: 519-550.
5. Dinarello, C. A., Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011. 117: 3720-3732.
6. Gross, O., Thomas, C. J., Guarda, G. andTschopp, J., The inflammasome: an integrated view. Immunol. Rev. 2011. 243: 136-151.
7. Dinarello, C. A., The interleukin-1 family: 10 years of discovery. FASEB J. 1994. 8: 1314-1325.
8. Carruth, L. M., Demczuk, S. and Mizel, S. B., Involvement of a calpain-like protease in the processing of the murine interleukin 1 alpha precursor. J. Biol. Chem. 1991. 266: 12162-12167.
9. Gu, Y., Kuida, K., Tsutsui, H., Ku, G., Hsiao, K., Fleming, M. A., Hayashi, N. et al., Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. Science 1997. 275: 206-209.
10. Kuida, K., Lippke, J. A., Ku, G., Harding, M. W., Livingston, D. J., Su, M. S. and Flavell, R. A., Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science 1995. 267: 2000-2003.
11. Keller, M., Ruegg, A., Werner, S. and Beer, H. D., Active caspase-1 is a regulator of unconventional protein secretion. Cell 2008. 132: 818-831.
12. Fettelschoss, A., Kistowska, M., LeibundGut-Landmann, S., Beer, H. D., Johansen, P., Senti, G., Contassot, E. et al., Inflammasome activation and IL-1beta target IL-1alpha for secretion as opposed to surface expression. Proc. Natl. Acad. Sci. USA 2011. 108: 18055-18060.
13. Dinarello, C. A., Biologic basis for interleukin-1 in disease. Blood 1996. 87: 2095-2147.
14. Cohen, I., Rider, P., Carmi, Y., Braiman, A., Dotan, S., White, M. R., Voronov, E. et al., Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Proc. Natl. Acad. Sci. USA 2010. 107: 2574-2579.
15. Freigang, S., Ampenberger, F., Spohn, G., Heer, S., Shamshiev, A. T., Kisielow, J., Hersberger, M. et al., Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis. Eur. J. Immunol. 2011. 41: 2040-2051.
16. Wen, H., Ting, J. P. and O'Neill, L. A., A role for the NLRP3 inflammasome in metabolic diseases-did Warburg miss inflammation? Nat. Immunol. 2012. 13: 352-357.
17. Chamberlain, J., Francis, S., Brookes, Z., Shaw, G., Graham, D., Alp, N. J., Dower, S. et al., Interleukin-1 regulates multiple atherogenic mechanisms in response to fat feeding. PLoS One 2009. 4: e5073.
18. Chi, H., Messas, E., Levine, R. A., Graves, D. T. and Amar, S., Interleukin-1 receptor signaling mediates atherosclerosis associated with bacterial exposure and/or a high-fat diet in a murine apolipoprotein E heterozygote model: pharmacotherapeutic implications. Circulation 2004. 110: 1678-1685.
19. Kirii, H., Niwa, T., Yamada, Y., Wada, H., Saito, K., Iwakura, Y., Asano, M. et al., Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb. Vasc. Biol. 2003. 23: 656-660.
20. Merhi-Soussi, F., Kwak, B. R., Magne, D., Chadjichristos, C., Berti, M., Pelli, G., James, R. W. et al., Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc. Res. 2005. 66: 583-593.
21. Kamari, Y., Werman-Venkert, R., Shaish, A., Werman, A., Harari, A., Gonen, A., Voronov, E. et al., Differential role and tissue specificity of interleukin-1alpha gene expression in atherogenesis and lipid metabolism. Atherosclerosis 2007. 195: 31-38.
22. Rader, D. J. and Daugherty, A., Translating molecular discoveries into new therapies for atherosclerosis. Nature 2008. 451: 904-913.
23. Bachmann, M. F. and Dyer, M. R., Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nat. Rev. Drug Discov. 2004. 3: 81-88.
24. Spohn, G., Keller, I., Beck, M., Grest, P., Jennings, G. T. and Bachmann, M. F., Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur. J. Immunol. 2008. 38: 877-887.
25. Guler, R., Parihar, S. P., Spohn, G., Johansen, P., Brombacher, F. and Bachmann, M. F., Blocking IL-1alpha but not IL-1beta increases susceptibility to chronic Mycobacterium tuberculosis infection in mice. Vaccine 2011. 29: 1339-1346.
26. Patel, S. S., Thiagarajan, R., Willerson, J. T. and Yeh, E. T., Inhibition of alpha4 integrin and ICAM-1 markedly attenuate macrophage homing to atherosclerotic plaques in ApoE-deficient mice. Circulation 1998. 97: 75-81.
27. Cybulsky, M. I., Iiyama, K., Li, H., Zhu, S., Chen, M., Iiyama, M., Davis, V. et al., A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J. Clin. Invest. 2001. 107: 1255-1262.
28. Dansky, H. M., Charlton, S. A., Harper, M. M. and Smith, J. D., T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. USA 1997. 94: 4642-4646.
29. Galkina, E. and Ley, K., Vascular adhesion molecules in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2007. 27: 2292-2301.
30. Galkina, E. and Ley, K., Immune and inflammatory mechanisms of atherosclerosis (*). Annu. Rev. Immunol. 2009. 27: 165-197.
31. Guzik, T. J., Hoch, N. E., Brown, K. A., McCann, L. A., Rahman, A., Dikalov, S., Goronzy, J. et al., Role of the T-cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J. Exp. Med. 2007. 204: 2449-2460.
32. Tangirala, R. K., Rubin, E. M. and Palinski, W., Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J. Lipid. Res. 1995. 36: 2320-2328.
33. Paigen, B., Morrow, A., Holmes, P. A., Mitchell, D. and Williams, R. A., Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 1987. 68: 231-240.
34. Zhou, X., Caligiuri, G., Hamsten, A., Lefvert, A. K. and Hansson, G. K., LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2001. 21: 108-114.
35. Ricci, R., Sumara, G., Sumara, I., Rozenberg, I., Kurrer, M., Akhmedov, A., Hersberger, M. et al., Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis. Science 2004. 306: 1558-1561.